BIT:1LLY • US5324571083
The current stock price of 1LLY.MI is 835.5 EUR. Today 1LLY.MI is down by -3.33%. In the past month the price decreased by -6.16%. In the past year, price increased by 5.77%.
ChartMill assigns a technical rating of 3 / 10 to 1LLY.MI. When comparing the yearly performance of all stocks, 1LLY.MI is a bad performer in the overall market: 68.92% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to 1LLY.MI. While 1LLY.MI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
On February 4, 2026 1LLY.MI reported an EPS of 7.54 and a revenue of 19.29B. The company beat EPS expectations (11.92% surprise) and beat revenue expectations (6.36% surprise).
37 analysts have analysed 1LLY.MI and the average price target is 1038.08 EUR. This implies a price increase of 24.25% is expected in the next year compared to the current price of 835.5.
For the next year, analysts expect an EPS growth of 38.64% and a revenue growth 28.68% for 1LLY.MI
Over the last trailing twelve months 1LLY.MI reported a non-GAAP Earnings per Share(EPS) of 20.84. The EPS increased by 86.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.99% | ||
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| Debt/Equity | 1.72 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.04 | 187.74B | ||
| SNW | SANOFI | 9.04 | 187.692B | ||
| 1SAN | SANOFI | 9.02 | 187.378B | ||
| UNC | UCB SA | 24.38 | 51.176B | ||
| UCB | UCB SA | 24.41 | 50.164B | ||
| MRK | MERCK KGAA | 12.81 | 49.217B | ||
| BAYN | BAYER AG-REG | 7.45 | 37.111B | ||
| 1BAYN | BAYER AG-REG | 7.65 | 36.973B | ||
| IPN | IPSEN | 14.11 | 13.795B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.059B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.15 | 9.95B | ||
| VIRP | VIRBAC SA | 16.3 | 2.907B | ||
| DMP | DERMAPHARM HOLDING SE | 15.26 | 2.062B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 47000
Phone: 13172762000
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
The current stock price of 1LLY.MI is 835.5 EUR. The price decreased by -3.33% in the last trading session.
ELI LILLY & CO (1LLY.MI) has a dividend yield of 0.68%. The yearly dividend amount is currently 4.82.
1LLY.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1LLY.MI.
You can find the ownership structure of ELI LILLY & CO (1LLY.MI) on the Ownership tab.